ClinicalTrials.gg
CompletedNCT00359112Updated May 18, 2009

AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes

A Phase 3 interventional study of metformin and sulphonylurea in Non-Insulin-Dependent Diabetes Mellitus, sponsored by GlaxoSmithKline. Completed at 142 sites in 11 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-05-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
544
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
38th of 287
544 · median 100
Started
2004
with 7 others
Phase 3
72 of 293
1 open now
Registered
31st of 293
by date
Lead sponsor
12 of 293
GlaxoSmithKline

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 38th largest by enrollment of the 287 interventional ones that give a count, is one of 8 that started in 2004, is one of 72 in phase 3, and was the 31st registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares the effects of Avandamet (rosiglitazone maleate/metformin) treatment and metformin plus sulphonylurea treatment in overweight people with type 2 diabetes.

03

Conditions studied

  • Non-Insulin-Dependent Diabetes Mellitus

Keywords

  • Type 2 diabetes
  • overweight
  • AVANDAMET
  • metformin
  • sulphonylurea
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > or = to 25 kg/m2.
  • > or =7% and \< or =10% at screening.
  • FPG > or = 7.0mmol/L (126mg/dL) at visit 2.
  • Receiving at least 0.85g of metformin at constant dose(s) for at least 8 weeks prior to visit 1a.
  • Female subjects must be or using effective measures.

Exclusion criteria

Exclusion criteria:

  • Use of any other oral antidiabetic drug other than metformin within 12 weeks prior to screening.
  • Subjects with ongoing oedema requiring pharmacological treatment or with a history of oedema requiring pharmacological treatment.
  • Subjects with a history of severe hypoglycaemia.
  • Renal disease or renal dysfunction.
  • Presence of clinically significant hepatic disease.
  • Presence of unstable or severe angina or known grade I-IV congestive heart failure.
  • Subjects who have had a previous myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft or cerebrovascular accident within 3 months prior to screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
544 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c level from baseline following 52 weeks of treatment.

Secondary outcomes

  1. Change in FPG (fasting plasma glucose)

  2. insulin sensitivity

  3. beta cell function

  4. change in PAI-1

  5. CRP

  6. number of hypoglycaemic events

  7. Change in 24 hr ABPM

  8. Diabetes treatment satisfaction.

07

Study locations

142 sites
  • GSK Investigational Site
    Brugge, 8000, Belgium
  • GSK Investigational Site
    Bruxelles, 1030, Belgium
  • GSK Investigational Site
    Bruxelles, 1210, Belgium
  • GSK Investigational Site
    Heverlee, 3001, Belgium
  • GSK Investigational Site
    Landen, 3400, Belgium
  • GSK Investigational Site
    Namur (Champion), 5020, Belgium
  • GSK Investigational Site
    Oostham, 3945, Belgium
  • GSK Investigational Site
    Petit-Rechain, 4800, Belgium
  • GSK Investigational Site
    Tessenderlo, 3980, Belgium
  • GSK Investigational Site
    Tremelo, 3120, Belgium
  • GSK Investigational Site
    Willebroek, 2830, Belgium
  • GSK Investigational Site
    Zandhoven (Pulle), 2243, Belgium
  • GSK Investigational Site
    Roubaix, Nord-Pas-de-Calais 59100, France
  • GSK Investigational Site
    Anzin, 59410, France
  • GSK Investigational Site
    Briollay, 49125, France
  • GSK Investigational Site
    Commelle Vernay, 42120, France
  • GSK Investigational Site
    Cremeaux, 42260, France
  • GSK Investigational Site
    Evron, 53600, France
  • GSK Investigational Site
    Laval, 53000, France
  • GSK Investigational Site
    Louverne, 53950, France
  • GSK Investigational Site
    Lyon, 69007, France
  • GSK Investigational Site
    Paris, 75015, France
  • GSK Investigational Site
    Roanne, 42300, France
  • GSK Investigational Site
    Saint Ouen, 93400, France
  • GSK Investigational Site
    Sainte Suzanne, 53270, France
  • GSK Investigational Site
    Segré, 49500, France
  • GSK Investigational Site
    Venissieux, 69200, France
  • GSK Investigational Site
    Gueglingen, Baden-Wuerttemberg 74363, Germany
  • GSK Investigational Site
    Kippenheim, Baden-Wuerttemberg 77971, Germany
  • GSK Investigational Site
    Koenigsfeld, Baden-Wuerttemberg 78126, Germany
  • GSK Investigational Site
    Waldshut-Tiengen, Baden-Wuerttemberg 79961, Germany
  • GSK Investigational Site
    Weinheim, Baden-Wuerttemberg 69469, Germany
  • GSK Investigational Site
    Grafing, Bayern 85567, Germany
  • GSK Investigational Site
    Herzogenaurach, Bayern 91074, Germany
  • GSK Investigational Site
    Immenstadt, Bayern 87509, Germany
  • GSK Investigational Site
    Oberteisendorf, Bayern 83317, Germany
  • GSK Investigational Site
    Saaldorf-Surheim, Bayern 83416, Germany
  • GSK Investigational Site
    Wallerfing, Bayern 94574, Germany
  • GSK Investigational Site
    Wuerzburg, Bayern 97072, Germany
  • GSK Investigational Site
    Grossalmerode, Hessen 37247, Germany
  • GSK Investigational Site
    Einbeck, Niedersachsen 37574, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30519, Germany
  • GSK Investigational Site
    Isernhagen, Niedersachsen 30916, Germany
  • GSK Investigational Site
    Papenburg, Niedersachsen 26871, Germany
  • GSK Investigational Site
    Beckum, Nordrhein-Westfalen 59269, Germany
  • GSK Investigational Site
    Bergkamen-Rünthe, Nordrhein-Westfalen 59192, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44869, Germany
  • GSK Investigational Site
    Dinslaken, Nordrhein-Westfalen 46537, Germany
  • GSK Investigational Site
    Dortmund, Nordrhein-Westfalen 44137, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45134, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Goch, Nordrhein-Westfalen 47574, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 51069, Germany
  • GSK Investigational Site
    Viersen, Nordrhein-Westfalen 41749, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55116, Germany
  • GSK Investigational Site
    Neuwied, Rheinland-Pfalz 56564, Germany
  • GSK Investigational Site
    Rhaunen, Rheinland-Pfalz 55624, Germany
  • GSK Investigational Site
    Speyer, Rheinland-Pfalz 67346, Germany
  • GSK Investigational Site
    Saarlouis, Saarland 66740, Germany
  • GSK Investigational Site
    Wolmirstedt, Sachsen-Anhalt 39326, Germany
  • GSK Investigational Site
    Dresden, Sachsen 01219, Germany
  • GSK Investigational Site
    Elmshorn, Schleswig-Holstein 25335, Germany
  • GSK Investigational Site
    Blanchardstown, 15, Ireland
  • GSK Investigational Site
    Dublin, 8, Ireland
  • GSK Investigational Site
    Dublin, 9, Ireland
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Ferrara, Emilia-Romagna 44100, Italy
  • GSK Investigational Site
    Ravenna, Emilia-Romagna 48100, Italy
  • GSK Investigational Site
    Arenzano (GE), Liguria 16011, Italy
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Sassari, Sardegna 07100, Italy
  • GSK Investigational Site
    Città di Castello (PG), Umbria 06012, Italy
  • GSK Investigational Site
    Terni, Umbria 05100, Italy
  • GSK Investigational Site
    Kaunas, LT-44320, Lithuania
  • GSK Investigational Site
    Kaunas, LT-49335, Lithuania
  • GSK Investigational Site
    Vilnius, LT-07156, Lithuania
  • GSK Investigational Site
    Vilnius, LT-08661, Lithuania
  • GSK Investigational Site
    Tijuana, Baja California Norte 22320, Mexico
  • GSK Investigational Site
    Pachuca, Hidalgo 42039, Mexico
  • GSK Investigational Site
    Guadalajara, Jalisco 44340, Mexico
  • GSK Investigational Site
    Durango, 3400, Mexico
  • GSK Investigational Site
    Mexico, D.F., 11850, Mexico
  • GSK Investigational Site
    Beek En Donk, 5741 CG, Netherlands
  • GSK Investigational Site
    Beerzerveld, 7685 PG, Netherlands
  • GSK Investigational Site
    Den Haag, 2582 LJ, Netherlands
  • GSK Investigational Site
    Heerlen, 6416 EG, Netherlands
  • GSK Investigational Site
    Hoogvliet, 3192 JN, Netherlands
  • GSK Investigational Site
    Landgraaf, 6373 JS, Netherlands
  • GSK Investigational Site
    Musselkanaal, 9581 AJ, Netherlands
  • GSK Investigational Site
    Oude Pekela, 9665 AR, Netherlands
  • GSK Investigational Site
    Spijkenisse, 3207 NB, Netherlands
  • GSK Investigational Site
    Woerden, 3443 GG, Netherlands
  • GSK Investigational Site
    Zaandam, 1504 JA, Netherlands
  • GSK Investigational Site
    Zieuwent, 7136 KH, Netherlands
  • GSK Investigational Site
    Alcobendas/Madrid, 28100, Spain
  • GSK Investigational Site
    Alcora/Castellón, 12110, Spain
  • GSK Investigational Site
    Alicante, Spain
  • GSK Investigational Site
    Alzira, 46600, Spain
  • GSK Investigational Site
    Artana/Castellón, 12527, Spain
  • GSK Investigational Site
    Barcelona, 08015, Spain

Showing the first 100 of 142 sites across 11 countries. Choose a country and city above to see the rest.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 18, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00359112
Lead sponsor
GlaxoSmithKline
First posted
Aug 1, 2006
Start date
Feb 2004
Last update
May 18, 2009

Study contacts

GSK Clinical Trials, DM, FRCP
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Rosiglitazone-metformin combination

Start the discussion